Lumexa Imaging's Dr. Kemp Joins RSNA Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy LMRI?
Source: PRnewswire
- Leadership Change: Dr. Jennifer L. Kemp, Chair of Lumexa Imaging's Center for Quality, has been elected to the Board of Directors of the Radiological Society of North America, reflecting the company's clinical leadership and the vital role of physicians in radiology.
- Patient Experience Enhancement: In her role as Chief of Patient Experience at Scanslated, Dr. Kemp leads initiatives to improve patient understanding of radiology results, showcasing the company's commitment to innovation in patient engagement.
- Technology Platform Utilization: Lumexa Imaging has utilized Scanslated's AI-driven software to provide over 2 million patients with clear radiology reports, significantly enhancing their likelihood of choosing Lumexa Imaging centers in the future.
- Industry Development Commitment: Dr. Kemp's role at RSNA will help guide the future of radiology, ensuring high-quality patient care while strengthening the voice of radiologists, aligning with Lumexa Imaging's commitment to clinical excellence and patient experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMRI
Wall Street analysts forecast LMRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMRI is 22.71 USD with a low forecast of 22.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.140
Low
22.00
Averages
22.71
High
23.00
Current: 10.140
Low
22.00
Averages
22.71
High
23.00
About LMRI
Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Leadership Change: Dr. Jennifer L. Kemp, Chair of Lumexa Imaging's Center for Quality, has been elected to the Board of Directors of the Radiological Society of North America, reflecting the company's clinical leadership and the vital role of physicians in radiology.
- Patient Experience Enhancement: In her role as Chief of Patient Experience at Scanslated, Dr. Kemp leads initiatives to improve patient understanding of radiology results, showcasing the company's commitment to innovation in patient engagement.
- Technology Platform Utilization: Lumexa Imaging has utilized Scanslated's AI-driven software to provide over 2 million patients with clear radiology reports, significantly enhancing their likelihood of choosing Lumexa Imaging centers in the future.
- Industry Development Commitment: Dr. Kemp's role at RSNA will help guide the future of radiology, ensuring high-quality patient care while strengthening the voice of radiologists, aligning with Lumexa Imaging's commitment to clinical excellence and patient experience.
See More
- Network Expansion: Lumexa Imaging set a company record by opening nine new imaging centers in 2025, increasing its total to over 185 centers across 13 states, significantly enhancing its market coverage and service capabilities nationwide.
- Strategic Growth: The new centers not only strengthen Lumexa Imaging's presence in rapidly growing metropolitan areas but also meet the rising patient demand for high-quality, cost-effective imaging services, driving future revenue growth for the company.
- Patient-Centric Approach: The company is focused on improving patient experiences by extending operating hours and providing easily accessible retail locations, which enhances patient satisfaction and strengthens its competitive position in the market.
- Future Outlook: Lumexa Imaging plans to continue expanding its network of imaging centers in 2026, further solidifying its leadership in the national imaging services market and is expected to deliver sustained growth and returns for shareholders.
See More
- Network Expansion: Lumexa Imaging set a record by opening nine new imaging centers in 2025, increasing its total to over 185 centers across 13 states, significantly enhancing the company's market coverage and service capabilities nationwide.
- Patient Service Enhancement: The new centers not only improve the patient experience for imaging exams but also make it easier for patients to complete MRIs, CTs, and PET/CTs through extended hours and convenient retail locations, thereby increasing accessibility to healthcare services.
- Strategic Growth: The Chief Growth Officer stated that Lumexa Imaging's de novo growth strategy focuses on high-growth metropolitan statistical areas, which is expected to continue driving business growth in 2026 and further solidify its position as the second-largest provider in the imaging services market.
- Future Outlook: With an aging population and rising chronic conditions, Lumexa Imaging plans to continue opening more new centers in collaboration with joint venture partners to meet the increasing healthcare demand, ensuring sustained value for both shareholders and patients.
See More
- Executive Participation: Lumexa Imaging's CEO Caitlin Zulla and CFO Tony Martin will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting the company's leadership in outpatient imaging services.
- Market Position: As of September 30, 2025, Lumexa Imaging operates 184 imaging centers, making it the second-largest outpatient imaging service provider in the U.S., underscoring its significance in the rapidly growing healthcare market.
- Partnerships: The company has established eight joint ventures with health systems, further enhancing its market reach and service capabilities, aiming to improve accessibility and quality of healthcare services through collaboration.
- Investor Relations: Lumexa Imaging provides an online webcast link and related presentation materials, aiming to enhance engagement with investors through transparent information sharing, thereby improving the company's image and trust in the capital markets.
See More
- IPO Pricing: Lumexa Imaging successfully priced its initial public offering at $18.50 per share for 25 million shares in December, reflecting market confidence in its diagnostic imaging services and expected to provide substantial funding for its expansion plans.
- Market Footprint: As of September 30, 2025, Lumexa Imaging operates 184 outpatient imaging centers across 13 states, making it the second-largest imaging center network in the U.S., thereby enhancing its competitive position in the healthcare services market.
- Growth Strategy: The company is prioritizing same-center growth through a dedicated sales force targeting high-value referral sources, which is estimated to provide a sustained ~100 basis point boost to overall growth, demonstrating the effectiveness of its commercial strategy.
- Digital Marketing: Lumexa Imaging runs multiple digital marketing campaigns to attract price-sensitive consumers seeking imaging services, with this segment expected to grow as high-deductible insurance plans become more common, further driving the company's performance.
See More
- Analyst Rating Upgrade: TD Cowen analyst Ritu Baral initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $67, representing significant upside from Friday's close of $39.60, indicating strong market optimism about the company's future growth prospects.
- Positive Market Reaction: Following the analyst rating announcement, vTv Therapeutics' stock is expected to gain traction, with investors showing heightened interest in its potential market performance, which could attract more capital inflow.
- SharpLink Gaming Rating Boost: Cantor Fitzgerald analyst Brett Knoblauch initiated coverage on SharpLink Gaming Inc (NASDAQ:SBET) with an Overweight rating and a price target of $15, indicating a notable increase from Friday's close of $9.69, reflecting recognition of its business growth potential.
- Dual Ratings for Lumexa Imaging: Both Leerink Partners and Jefferies initiated coverage on Lumexa Imaging Holdings Inc (NASDAQ:LMRI) with Outperform ratings and a price target of $23, showcasing a strong consensus in the market regarding the company's promising outlook.
See More











